Showing 1671-1680 of 2526 results for "".
- Glaukos Receives EU MDR Certification for iStent infinite and iStent inject Whttps://modernod.com/news/glaukos-announces-european-union-mdr-certification-for-istent-infinite-and-istent-inject-w/2482868/Glaukos received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite, along with several of its other MIGS technologies, including iStent inject W. Glauko
- The European Commission (EC) Approves Eylea 8 mg for Extended Treatment Intervals of Up to 6 Monthshttps://modernod.com/news/the-european-commission-ec-approves-eylea-8-mg-for-extended-treatment-intervals-of-up-to-6-months/2482867/The European Commission (EC) has granted a label extension in the European Union (EU) for Eylea 8 mg with extended treatment intervals of up to 6 months for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Eylea 8 mg was previously
- France First in EU to Reimburse Hoya MiYOSMART Lens for Childhood Myopiahttps://modernod.com/news/france-first-in-eu-to-reimburse-hoya-miyosmart-lens-for-childhood-myopia/2482856/France will begin reimbursing Hoya Vision Care’s MiYOSMART myopia control spectacle lenses for eligible children starting July 1. This move makes France as the first country in the European Union to provide public coverage for the lenses.
- ViGeneron Rebrands as VeonGen Therapeutics; Announces FDA Rare Pediatric Disease Designation for Lead Gene Therapyhttps://modernod.com/news/vigeneron-rebrands-as-veongen-therapeutics-announces-fda-rare-pediatric-disease-designation-for-lead-gene-therapy/2482837/VeonGen Therapeutics announced its rebranding from ViGeneron to reflect its evolution into a clinical-stage genetic medicine company focused on developing transformative gene therapies for patients with high unmet medical needs. VeonGen has advanc
- NIH Researchers Identify Brain Circuits Responsible for Visual Acuityhttps://modernod.com/news/nih-researchers-identify-brain-circuits-responsible-for-visual-acuity/2482836/Researchers at the National Institutes of Health (NIH) says they have identified specific brain circuits vital to visual acuity and uncovered how these circuits are disrupted by damage to retinal cells, a discovery that could reshape the future of vision resto
- Bausch + Lomb Launches Blink Nourish and Blink Boost Lubricating Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-blink-nourish-and-blink-boost-lubricating-eye-drops-in-the-us/2482834/Bausch + Lomb announced the US launch of Blink Nourish and Blink Boost lubricating eye drops. According to B+L, both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry e
- Haag-Streit Launches Cornea Map Toric Assessment Feature for the Lenstarhttps://modernod.com/news/haag-streit-launches-cornea-map-toric-assessment-feature-for-the-lenstar/2482833/Haag-Streit has unveiled the the cornea map for its flagship Lenstar 900 optical biometer. This feature is designed to provide clinic
- Opus Genetics Phase 3 Trial for Phentolamine Ophthalmic Solution Meets Primary Endpoint for Night Visionhttps://modernod.com/news/opus-genetics-phase-3-trial-for-phentolamine-ophthalmic-solution-meets-primary-endpoint-for-night-vision/2482828/Opus Genetics announced positive topline results from LYNX-2, a phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Patients who undergo kera
- Study: Long-Approved HIV Drug May Improve Vision in Patients with DMEhttps://modernod.com/news/study-long-approved-hiv-drug-may-improve-vision-in-patients-diabetic-macular-edema-patients/2482826/A clinical trial suggests that lamivudinem, an inexpensive, long-approved HIV drug, can improve vision in patients with diabetic macular edema more effectively and at a lower cost than many existing treatments, according to researchers at the University of Virginia (UVA Health
- CE-Mark Granted to deepeye Medical for AI Tool for Retinal Therapy Planninghttps://modernod.com/news/ce-mark-granted-to-deepeye-medical-for-ai-tool-for-retinal-therapy-planning/2482816/deepeye Medical has received CE Mark for its deepeye TPS¹ (Therapy Planning Support) platform. The Class IIa approval was made under the EU Medical Device Regulation (MDR 2017/745), following certification by the Notified Body